You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for WAY 213613
WAY 213613 is a potent, non-substrate inhibitor of EAAT2 (GLT-1) that displays > 44-fold selectivity over EAAT1 and EAAT3 (IC50 values are 85, 3787 and 5004 nM for EAAT2, EAAT3 and EAAT1 respectively). Another study has found WAY 213613 has 12 - 26-fold selectivity for EAAT2 over EAAT1, EAAT3 and EAAT4 (IC50 values are 0.071, 0.86, 1.5 and 1.9 nM for EAAT2, EAAT1, EAAT4 and EAAT3, respectively). Exhibits no activity towards ionotropic and metabotropic glutamate receptors.
Compound Libraries for WAY 213613
Technical Data for WAY 213613
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for WAY 213613
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for WAY 213613
The following data is based on the product molecular weight 415.19. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.41 mL||12.04 mL||24.09 mL|
|5 mM||0.48 mL||2.41 mL||4.82 mL|
|10 mM||0.24 mL||1.2 mL||2.41 mL|
|50 mM||0.05 mL||0.24 mL||0.48 mL|
References for WAY 213613
References are publications that support the biological activity of the product.
Dunlop et al (2005) Characterization of novel aryl-ether, biaryl, and fluorene aspartic acid and diaminopropionic acid analogs as potent inhibitors of the high-affinity glutamate transporter EAAT2. Mol.Pharmacol. 68 974 PMID: 16014807
Beart and Shea (2007) Transporters for L-glutamate: an update on their molecular pharmacology and pathological involvement. Br.J.Pharmacol. 150 5 PMID: 17088867
Fu et al (2018) Chemoenzymatic synthesis and pharmacological characterization of functionalized aspartate analogues as novel excitatory amino acid transporter inhibitors. J.Med.Chem. 61 7741 PMID: 30011368
If you know of a relevant reference for WAY 213613, please let us know.
View Related Products by Product Action
Keywords: WAY 213613, WAY 213613 supplier, Potent, non-, EAAT2, inhibitors, inhibits, Excitatory, Amino, Acid, Transporters, GLT-1, Glutamate, Monoamine, Neurotransmitter, WAY213613, 2652, Tocris Bioscience
3 Citations for WAY 213613
Citations are publications that use Tocris products. Selected citations for WAY 213613 include:
Dumont et al (2014) Differential regulation of glutamate transporter subtypes by pro-inflammatory cytokine TNF-α in cortical astrocytes from a rat model of amyotrophic lateral sclerosis. Evid Based Complement Alternat Med 9 e97649 PMID: 24836816
Brancaccio et al (2017) Astrocytes Control Circadian Timekeeping in the Suprachiasmatic Nucleus via Glutamatergic Signaling. Neuron 93 1420 PMID: 28285822
Falcucci et al (2019) Novel positive allosteric modulators of glutamate transport have neuroprotective properties in an in vitro excitotoxic model. ACS Chem Neurosci 10 3437 PMID: 31257852
Do you know of a great paper that uses WAY 213613 from Tocris? Please let us know.
Reviews for WAY 213613
Average Rating: 4 (Based on 1 Review.)
Have you used WAY 213613?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
WAY 213613 (1 μM)
Incubate for 24h
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.